Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate
- 8 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (7), 1136-1144
- https://doi.org/10.1093/ndt/gfaa053
Abstract
Background Anemia of chronic kidney disease (CKD) is, in part, caused by hepcidin-mediated impaired iron absorption. However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients. The mechanism and sites of intestinal absorption of iron contained in FC were explored here. Methods Eight-week old rats were randomized to sham-operated or 5/6 nephrectomized (CKD) groups and fed either regular rat chow or rat chow containing 4% FC for 6 weeks. They were then euthanized, and tissues were processed for histological and biochemical analysis using Prussian blue staining, Western blot analysis to quantify intestinal epithelial tight junction proteins and real-time PCR to measure Fatty Acid receptors 2 (FFA2) and 3 (FFA3) expressions. Results CKD rats exhibited hypertension, anemia, azotemia, and hyperphosphatemia. FC-treated CKD rats showed significant reductions in blood pressure, serum urea, phosphate and creatinine levels and higher serum iron and blood hemoglobin levels. This was associated with marked increase in iron content of the epithelial and subepithelial wall of the descending colon and modest iron deposits in the proximal tubular epithelial cells of their remnant kidneys. No significant difference was found in hepatic tissue iron content between untreated and FC-treated CKD or control groups. Distal colon’s epithelial tight Junction proteins, Occludin, JAM-1 and ZO-1 were markedly reduced in the CKD groups. The FFA2 expression in the jejunum and FFA3 expression in the distal colon were significantly reduced in the CKD rats and markedly increased with FC administration. Conclusion Iron contained in the phosphate binder, FC, is absorbed by the distal colon of the CKD animals via disrupted colonic epithelial barrier and upregulation of short chain fatty acid transporters.This publication has 39 references indexed in Scilit:
- Understanding Iron: Promoting Its Safe Use in Patients With Chronic Kidney Failure Treated by HemodialysisAmerican Journal of Kidney Diseases, 2013
- Role of Urea in Intestinal Barrier Dysfunction and Disruption of Epithelial Tight Junction in Chronic Kidney DiseaseAmerican Journal of Nephrology, 2012
- Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targetsFrontiers in Endocrinology, 2012
- Iron Sucrose Promotes Endothelial Injury and Dysfunction and Monocyte Adhesion/InfiltrationAmerican Journal of Nephrology, 2011
- Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucroseBioMetals, 2011
- Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysisNephrology, 2010
- Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failureAmerican Journal of Physiology-Renal Physiology, 2010
- Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Intra-Renal Angiotensin II/AT1Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass ReductionThe Journal of pharmacology and experimental therapeutics, 2007
- Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysisKidney International, 2001